Ultragenyx opens new gene therapy manufacturing site in Massachusetts
The rare disease player Ultragenyx will produce its gene therapies in-house as it opens the doors to a new manufacturing facility, which will lessen its reliance on external contract manufacturers.
Ultragenyx announced Wednesday that it officially opened its 110,000-square-foot manufacturing facility on a 10.7-acre site in the Boston suburb of Bedford, MA. The site enables Ultragenyx to produce gene therapies in 2,000-liter batches versus the industry standard of 50 liters per batch. Construction on the site began in 2020. The cost of the facility was not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
